US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Champion Industries, Inc.

0.0001

+0.0000

Volume:- -

Turnover:- -

Market Cap:5.59

PE:0.00

High:0.0001

Open:0.0001

Low:0.0001

Close:0.0001

Loading ...

Overview Company News Filings

Bristol Myers gets positive CHMP opinion for Opdivo plus Yervoy

Bavarian Nordic Receives Positive CHMP Opinion for Chikungunya Vaccine for Persons Aged 12 and Older

Is BridgeBio Pharma, Inc. (BBIO) the Unstoppable Stock to Buy in 2025?

FDA approves IV maintenance dosing of Leqembi® (lecanemab-irmb) for the treatment of early Alzheimer's Disease in the US

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome

Geron Corporation (GERN) Stock: An Under $5 Gem with Biggest Upside Potential

FDA Okays LLY's Omvoh for Second Inflammatory Bowel Disease Condition

SNY's Subcutaneous Sarclisa Proves Non-Inferior to IV Formulation (Revised)

FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US

Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel

Geron Stock Rallies More Than 60% in a Year: Here's Why

Here’s Why Geron Corp. (NASDAQ:GERN) Crashed Today

Why Is Geron Corporation (GERN) the Best Long-Term Penny Stock to Buy According to Hedge Funds?

Why Is Geron Corporation (GERN) Among the Best Biotech Penny Stocks to Invest in Now?

Geron Corp. (GERN) Ends Trading Week Defying Market Bloodbath

Is Geron Corp. (GERN) the Biggest Loser of This Week?

Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A Deals

GILD Obtains Positive CHMP Opinion for Liver Disease Drug

CHMP Endorses Merck's Kidney Cancer Drug for Two Indications

GSK announces CHMP of the EMA recommended expanding approval of Jemperli

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CHMP/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"CHMP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CHMP\",,,,,undefined,":{"symbol":"CHMP","market":"US","secType":"STK","nameCN":"Champion Industries, Inc.","latestPrice":0.0001,"timestamp":1744920000000,"preClose":0.0001,"halted":0,"volume":0,"delay":15,"floatShares":0,"shares":55857,"eps":-23.033406,"marketStatus":"Market Closed","change":0,"latestTime":"04-17 16:00:00 EDT Delay","open":0.0001,"high":0.0001,"low":0.0001,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-23.033406,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"EXPERT","adjPreClose":0.0001,"volumeRatio":2.7777835648268714},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CHMP\",,,,,undefined,":{"symbol":"CHMP","floatShares":0,"roa":"-1.87%","roe":"-49.45%","lyrEps":-23.033406,"volumeRatio":2.7777835648268714,"shares":55857,"dividePrice":0,"high":0.0001,"amplitude":0,"preClose":0.0001,"low":0.0001,"week52Low":0.0001,"pbRate":"0.00","psRate":"0.00","week52High":0.0001,"institutionHeld":0,"latestPrice":0.0001,"eps":-23.033406,"divideRate":0,"volume":0,"delay":15,"ttmEps":-23.033406,"open":0.0001,"prevYearClose":0.0001,"prevWeekClose":0.0001,"prevMonthClose":0.0001,"prevQuarterClose":0.0001,"fiveDayClose":0.0001,"twentyDayClose":0.0001,"sixtyDayClose":0.0001},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CHMP\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2507548929","title":"Bristol Myers gets positive CHMP opinion for Opdivo plus Yervoy","url":"https://stock-news.laohu8.com/highlight/detail?id=2507548929","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507548929?lang=en_us&edition=fundamental","pubTime":"2025-01-31 20:07","pubTimestamp":1738325246,"startTime":"0","endTime":"0","summary":"Bristol Myers (BMY) Squibb announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended appro...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bristol-myers-gets-positive-chmp-opinion-for-opdivo-plus-yervoy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bristol-myers-gets-positive-chmp-opinion-for-opdivo-plus-yervoy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LU0882574055.USD","LU1868836757.USD","LU0456855351.SGD","LU1868836914.USD","LU2125154935.USD","BK4007","CHMP","LU2125154778.USD","LU0096364046.USD","BK4581","LU2133065610.SGD","IE00BSNM7G36.USD","LU1585245621.USD","LU1670710661.SGD","LU1670711040.USD","BK4559","BMY","LU0306806265.USD","BK4534","LU1074936037.SGD","LU0225284248.USD","LU0321505439.SGD","LU1261432733.SGD","MYE","LU1989771016.USD","IE0002141913.USD","LU1032466523.USD","LU1868837300.USD","LU1868836591.USD","LU0868494617.USD","BK4588","LU1670710588.SGD","LU1670711123.USD","LU0225771236.USD","LU2242652126.USD","LU1093756325.SGD","BK4532","IE00BFTCPJ56.SGD","BK4087","BK4126","IE00BJT1NW94.SGD","LU1430594728.SGD","LU1323610961.USD","IE0009355771.USD","LU1571399168.USD","LU2242646821.SGD","LU1291159041.SGD","LU0237698245.USD","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2507956551","title":"Bavarian Nordic Receives Positive CHMP Opinion for Chikungunya Vaccine for Persons Aged 12 and Older","url":"https://stock-news.laohu8.com/highlight/detail?id=2507956551","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507956551?lang=en_us&edition=fundamental","pubTime":"2025-01-31 18:50","pubTimestamp":1738320600,"startTime":"0","endTime":"0","summary":"First chikungunya vaccine recommended by the CHMP for persons as young as 12 years old.The virus-like particle  single-dose chikungunya vaccine is expected to launch in key European markets in the first half of 2025, pending final marketing authorization.COPENHAGEN, Denmark, January 31, 2025 – Bavarian Nordic A/S  today announced that the Committee for Medicinal Products for Human Use  of the European Medicines Agency  has adopted a positive opinion recommending marketing authorization for VIMKUNYA  for active immunization for the prevention of disease caused by chikungunya virus in individuals 12 years and older.The vaccine is also currently under priority review with the U.S. Food and Drug Administration , with a Prescription Drug User Fee Act  action date set for February 14, 2025.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bavarian-nordic-receives-positive-chmp-105000035.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4087","BK4588","MAA","CHMP","VLP","BK4215","BK4156","BVNKF","BVNRY","BK4139","BK4585"],"gpt_icon":0},{"id":"2507636836","title":"Is BridgeBio Pharma, Inc. (BBIO) the Unstoppable Stock to Buy in 2025?","url":"https://stock-news.laohu8.com/highlight/detail?id=2507636836","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507636836?lang=en_us&edition=fundamental","pubTime":"2025-01-30 05:00","pubTimestamp":1738184404,"startTime":"0","endTime":"0","summary":"We recently published a list of 10 Unstoppable Stocks to Buy in 2025. In this article, we are going to take a look at where BridgeBio Pharma, Inc.  stands against other unstoppable stocks to buy in 2025.As per the recent earnings update by FactSet dated 24thJanuary 2025, the Q4 2024 earnings season for the S&P 500 has seen a strong start. Notably, the percentage of S&P 500 companies publishing positive earnings surprises and the magnitude of earnings surprises are more than 10-year averages. The analysts anticipate YoY earnings growth rates of 11.3% and 11.6% for Q1 2025 and Q2 2025, respectively. For CY 2025, they project a YoY earnings growth of 14.8%.To list the 10 Unstoppable Stocks to Buy in 2025, we used a screener to filter out the companies having at least $2 billion of market capitalization. Next, we chose stocks that have gained more than 30% over the past 6 months and in which analysts expect an upside of at least 30%. Finally, th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bridgebio-pharma-inc-bbio-unstoppable-210004898.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QLD","USAW.SI","PSQ","BK4585","USJW.SI","TSYW.SI","BBIO","EU","BK4505","BK4588","NQmain","CHMP",".IXIC","BK4087","BK4139","BK4156","MNQmain","TQQQ","NVIW.SI","SQQQ","QID"],"gpt_icon":1},{"id":"2506614311","title":"FDA approves IV maintenance dosing of Leqembi® (lecanemab-irmb) for the treatment of early Alzheimer's Disease in the US","url":"https://stock-news.laohu8.com/highlight/detail?id=2506614311","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506614311?lang=en_us&edition=fundamental","pubTime":"2025-01-27 10:53","pubTimestamp":1737946380,"startTime":"0","endTime":"0","summary":"STOCKHOLM, Jan. 27, 2025 /PRNewswire/ -- BioArctic AB   today announced that the U.S. Food and Drug Administration  has approved BioArctic's partner Eisai's Supplemental Biologics License Application  for Leqembi as a once every four weeks intravenous  maintenance dosing. Leqembi is indicated for the treatment of Alzheimer's disease in patients with mild cognitive impairment  or mild dementia stage of disease in the U.S. . This approval means that patients who have completed the biweekly initiation phase of 18 months have the option to transition to a once every four weeks 10 mg/kg dosing regimen.Alzheimer's disease is caused by a continuous underlying neurotoxic process that begins before and continues after plaque removal. Continuous administration of Leqembi is of great value to patients as Leqembi works to fight Alzheimer's Disease in two ways: not only rapidly clearing the amyloid-beta (Aβ) plaque, but it also works to fight the progressive nature of Alzheimer's disease by continu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/fda-approves-iv-maintenance-dosing-025300601.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-approves-iv-maintenance-dosing-025300601.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4087","BRCTF","CHMP","AAIC","BK4110","MCI"],"gpt_icon":0},{"id":"2505854815","title":"X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2505854815","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505854815?lang=en_us&edition=fundamental","pubTime":"2025-01-24 20:36","pubTimestamp":1737722160,"startTime":"0","endTime":"0","summary":"Submission supported by positive results from global, Phase 3 4WHIM clinical trial; U.S. regulatory approval in WHIM syndrome granted in 2024 Decision on MAA expected in 1H 2026 BOSTON, Jan.  24, 2025","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/24/3014855/0/en/X4-Pharmaceuticals-Announces-EMA-Validation-of-Marketing-Authorization-Application-MAA-for-Mavorixafor-for-the-Treatment-of-WHIM-Syndrome.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4215","BK4588","MAA","BK4585","BK4087","CHMP"],"gpt_icon":0},{"id":"2505260950","title":"Geron Corporation (GERN) Stock: An Under $5 Gem with Biggest Upside Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2505260950","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505260950?lang=en_us&edition=fundamental","pubTime":"2025-01-21 11:02","pubTimestamp":1737428547,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 12 Stocks Under $5 With Biggest Upside Potential.In this article, we are going to take a look at where Geron Corporation  stands against other stocks under $5 with biggest upside potential.On January 20, Bloomberg reported that relief swept through the markets as it became clear that Donald Trump would not immediately impose China-specific tariffs on his first day in office, sparking a rally in US equity futures and a decline in the dollar.According to people familiar with the plans, the Trump administration is pivoting towards a more engagement-oriented approach with Beijing, rather than pursuing another trade war.The administration also plans to issue a memorandum directing federal agencies to study existing trade policies and relationships with China, Canada, and Mexico, rather than imposing new tariffs.Despite the positive economic indicators, Druckenmiller noted that the earnings yield to bond yield i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geron-corporation-gern-stock-under-030227751.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4087","BK4139","TQQQ","QID","BK4526","NVIW.SI","NQmain","PSQ",".IXIC","SQQQ","USAW.SI","MF","MNQmain","BK4539","USJW.SI","BK4113","BK4563","GERN","TSYW.SI","QLD","CHMP"],"gpt_icon":1},{"id":"2503291337","title":"FDA Okays LLY's Omvoh for Second Inflammatory Bowel Disease Condition","url":"https://stock-news.laohu8.com/highlight/detail?id=2503291337","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503291337?lang=en_us&edition=fundamental","pubTime":"2025-01-16 20:49","pubTimestamp":1737031740,"startTime":"0","endTime":"0","summary":"Eli Lilly and Company LLY announced that the FDA has granted approval to its drug, Omvoh , for its second inflammatory bowel disease  condition, Crohn's disease , in the United States. Omvoh was approved for its first IBD indication, moderately to severely active ulcerative colitis , in 2023. The drug is currently approved for UC in 44 countries.The approval of Omvoh for moderately to severely active CD in adults was based on data from the VIVID 1 study. The study met both its co-primary endpoints, showing significant improvement in clinical remission and endoscopic response at one year.Lilly is also studying Omvoh in theVIVID-2 open-label extension  study, evaluating the drug for up to three years in adults with moderately to severely active Crohn's disease. Among the patients who achieved clinical remission and endoscopic response at one yearin the VIVID-1 study, almost 90% maintained clinical remission with two years of continuous treatment with Omvoh in VIVID-2 OLE study.Lilly’s st","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-okays-llys-omvoh-second-124900551.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1934455863.HKD","ABBV","LU0097036916.USD","LU0109391861.USD","SNY","SG9999014567.USD","LU0545039389.USD","BK4516","LU0320765489.SGD","SG9999001440.SGD","IBD","LU1868837300.USD","LU0114720955.EUR","SGXZ31699556.SGD","LU1267930573.SGD","LU0949170772.SGD","LU1244550494.USD","LU0208291251.USD","CD","LU0310800379.SGD","LU2023251221.USD","LU0965509010.AUD","SG9999015978.USD","LU1718418525.SGD","MRK","LU0861579265.USD","LU0170899867.USD","IE00BDGV0183.EUR","BK4588","IE00BJT1NW94.SGD","LLY","LU0553294199.USD","LU0354030438.USD","SG9999015952.SGD","LU2089283258.USD","CHMP","SG9999003800.SGD","SGXZ99366536.SGD","LU1066051811.HKD","LU1244550221.USD","SG9999011175.SGD","IE00BFXG1179.USD","LU0070302665.USD","BK4550","LU1941712348.USD","SG9999014906.USD","LU1934455194.USD","BK4534","BK4599","LU0882574139.USD"],"gpt_icon":1},{"id":"2503547052","title":"SNY's Subcutaneous Sarclisa Proves Non-Inferior to IV Formulation (Revised)","url":"https://stock-news.laohu8.com/highlight/detail?id=2503547052","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503547052?lang=en_us&edition=fundamental","pubTime":"2025-01-14 17:16","pubTimestamp":1736846160,"startTime":"0","endTime":"0","summary":"Sanofi SNY announced that the phase III IRAKLIA study, which evaluated a fixed-dose subcutaneous  formulation of its blood cancer drug, Sarclisa  for the treatment of relapsed or refractory multiple myeloma  has met the co-primary endpoints.Data from the study showed that the new SC formulation of Sarclisa in combination with Bristol Myers’ BMY Pomalyst  and dexamethasone  when administered through an on-body delivery system  demonstrated non-inferiority in objective response rate  and observed concentration before dosing  as compared to currently approved intravenous  formulation of Sarclisa administered at a weight-based dose in combination with Pd in the given patient population.ORR and C trough were the two co-primary endpoints of the IRAKLIA study. It is also the first phase III study to evaluate the SC administration of a cancer drug via an OBDS. Per the company, OBDS is a substitute delivery method planned to improve the patient experience and currently available SC administrati","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/snys-subcutaneous-sarclisa-proves-non-091600551.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CTMX","LU1868837300.USD","BK4534","LU1032466523.USD","PBYI","SNY","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","BK4581","LU0096364046.USD","BK4139","IE00B2B36J28.USD","LU1670710661.SGD","LU0321505868.SGD","LU1670710588.SGD","LU1261432733.SGD","IE00BJJMRZ35.SGD","IE00BFXG1179.USD","LU2125154778.USD","BMY","LU0237698245.USD","IE0009355771.USD","LU1430594728.SGD","LU2360032135.SGD","LU1093756168.USD","BK4585","LU1291159041.SGD","LU1868836757.USD","LU2125154935.USD","LU0225284248.USD","LU1670711040.USD","IE0002141913.USD","BK4532","LU1323610961.USD","BK4588","LU0306807586.USD","LU0456855351.SGD","LU1571399168.USD","LU2242652126.USD","LU1989771016.USD","LU0321505439.SGD","CHMP","BK4007","LU1670711123.USD","LU0985481810.HKD","LU2133065610.SGD","BK4087","LU0882574055.USD","LU0114720955.EUR","LU0868494617.USD"],"gpt_icon":0},{"id":"2503599616","title":"FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US","url":"https://stock-news.laohu8.com/highlight/detail?id=2503599616","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503599616?lang=en_us&edition=fundamental","pubTime":"2025-01-14 10:51","pubTimestamp":1736823060,"startTime":"0","endTime":"0","summary":"STOCKHOLM, Jan. 14, 2025 /PRNewswire/ --BioArctic AB   today announced that the U.S. Food and Drug Administration  has accepted BioArctic's partner Eisai's Biologics License Application  for Leqembi subcutaneous autoinjector  for weekly maintenance dosingLeqembi is indicated for the treatment of Alzheimer's disease  in patients with Mild Cognitive Impairment  or mild dementia stage of disease . Leqembi is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration option. The Prescription Drug User Fee Act  action date has been set to August 31, 2025.The BLA is based on data from the Clarity AD  open-label extension  and modeling of observed data. If LEQEMBI subcutaneous maintenance dosing is approved by the FDA, LEQEMBI will be the only treatment for AD that can be administered subcutaneously at home using an autoinjector . The injection process is expected to take, on average, 15 seconds. The SC-AI 36","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/fda-accepts-biologics-license-application-025100211.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-accepts-biologics-license-application-025100211.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BRCTF","BK4139","MCI","CHMP","BK4087"],"gpt_icon":0},{"id":"2503340357","title":"Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel","url":"https://stock-news.laohu8.com/highlight/detail?id=2503340357","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503340357?lang=en_us&edition=fundamental","pubTime":"2025-01-13 14:00","pubTimestamp":1736748000,"startTime":"0","endTime":"0","summary":"Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon's biosimilar candidate to Eylea1Agreement builds on the proven and successful collaboration of c","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/13/3008103/0/en/Teva-Announces-Collaboration-to-Commercialize-Formycon-s-Biosimilar-Candidate-to-Eylea-aflibercept-in-major-parts-of-Europe-and-in-Israel.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4087","CHMP"],"gpt_icon":0},{"id":"2502513708","title":"Geron Stock Rallies More Than 60% in a Year: Here's Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2502513708","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502513708?lang=en_us&edition=fundamental","pubTime":"2025-01-08 23:33","pubTimestamp":1736350380,"startTime":"0","endTime":"0","summary":"For Geron Corporation GERN, 2024 was a transformational year as it saw the FDA approval and commercial launch of Rytelo for the treatment of low- to intermediate-1 risk myelodysplastic syndromes  with transfusion-dependent anemia in June.Geron’s shares have risen 61.1% in the past year against a decrease of 15.6% for the industry. Here we discuss some reasons for the same.In December, the Committee for Medicinal Products for Human Use  of the European Medicines Agency gave a positive opinion recommending the approval of Rytelo in the EU. The European Commissionis expected to give its decision regarding the approval of Rytelo in the first half of 2025.In the past 60 days, 2024 loss estimates for Geron have improved from 26 cents per share to 25 cents per share. For 2025, loss estimates have improved from 10 cents to 6 cents per share over the same timeframe.In the past 60 days, estimates for Halozyme Therapeutics’ 2025 earnings per share have increased from $4.80 to $4.81. In the past y","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geron-stock-rallies-more-60-153300239.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PBYI","CHMP","HALO","GERN","BK4196","BK4087","CSTL","LU0053671581.USD","BK4139"],"gpt_icon":0},{"id":"2501214703","title":"Here’s Why Geron Corp. (NASDAQ:GERN) Crashed Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2501214703","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501214703?lang=en_us&edition=fundamental","pubTime":"2025-01-07 10:20","pubTimestamp":1736216414,"startTime":"0","endTime":"0","summary":"Ten companies kicked off this week's trading mirroring a decline on Dow Jones with a series of catalysts dampening investor sentiment. In this article, let’s explore the reasons behind their decline.To come up with Monday's top losers, we considered only the stocks with at least $2 billion in market capitalization and $5 million in daily trading volume.A close-up of a laboratory technician in a laboratory, measuring a newly developed biopharmaceutical drug.Shares of Geron Corp. decreased by 3.92 percent on Monday to finish the day at $3.43 apiece as investors remained on the sidelines for further developments from the company.Earlier, the company reported net loss in the third quarter and the first nine months of the year. Albeit a lower net loss in the third quarter, its first nine months registered a higher loss of $149.2 million as compared with the $132.2 million registered year-on-year.Disclosure: None. This article is originally published atInsider Monkey.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-geron-corp-nasdaq-gern-022014378.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BKPKM429.USD","NDAQ","BK4139","GERN","BK4588","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU2095319765.USD","BK4585","BK4112","LU2210149790.SGD","CHMP","IE00B64PRP62.GBP",".IXIC","BK4087","LU2210150020.SGD","GERNW"],"gpt_icon":0},{"id":"2501262694","title":"Why Is Geron Corporation (GERN) the Best Long-Term Penny Stock to Buy According to Hedge Funds?","url":"https://stock-news.laohu8.com/highlight/detail?id=2501262694","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501262694?lang=en_us&edition=fundamental","pubTime":"2025-01-07 04:30","pubTimestamp":1736195446,"startTime":"0","endTime":"0","summary":"We recently published a list of the 12 Best Long-Term Penny Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Geron Corporation  stands against the other best long-term penny stocks to buy.What’s the Future Like for Small Cap Stocks in 2025?To curate the list of the 12 best long-term penny stocks to buy according to hedge funds, we used the Finviz stock screener and Seeking Alpha. Using the screener we got an initial list of penny stocks ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-geron-corporation-gern-best-203046301.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NVIW.SI","SQQQ","USJW.SI","NQmain","BK4139","BK4087","QID","CHMP","TSYW.SI","PSQ","TQQQ","QLD",".IXIC","MNQmain","USAW.SI","GERN"],"gpt_icon":1},{"id":"2500430896","title":"Why Is Geron Corporation (GERN) Among the Best Biotech Penny Stocks to Invest in Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2500430896","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500430896?lang=en_us&edition=fundamental","pubTime":"2025-01-01 01:54","pubTimestamp":1735667646,"startTime":"0","endTime":"0","summary":"We recently published a list of the 12 Best Biotech Penny Stocks To Invest In Now. In this article, we are going to take a look at where Geron Corporation  stands against the other best biotech penny stocks to invest in now.Recent performance data supports Goldman’s outlook. The iShares Biotech ETF climbed 7.7% in Q3, outperforming the Nasdaq Biotech Index and more than doubling the S&P 500’s 3.2% gain over the same period. For investors anticipating a continued decline in bond yields, Goldman suggests biotechnology stocks may offer more attractive exposure compared to other rate-sensitive equity sectors, which are more dependent on broader economic growth trends.Sears noted that small and emerging biotechnology companies have been at the forefront of this innovation. In 2023, approximately two-thirds of all clinical trials were initiated by small and emerging biotechnology firms, and about 56% of new drug substances approved by regulatory bodies originated from these smaller compa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-geron-corporation-gern-among-175406307.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4504","SQQQ","BK4113","BK4087","BK4526","GERN",".IXIC","LU1791807156.HKD","LU2237443622.USD","LU2237443895.HKD","MNQmain","BK4139","USAW.SI","LU2237438978.USD","IE0004091025.USD","CHMP","BK4585","QLD","IE0034235188.USD","BK4588","BK4563","NVIW.SI","BK4127","LU1668664300.SGD","BK4539","IE00BSNM7G36.USD","TSYW.SI","LU2237443549.SGD","QID","LU0106831901.USD","IE00B19Z3B42.SGD","BK4516","IE00B19Z3581.USD","LU2237443465.HKD","NQmain","TQQQ","MF","LU2237443978.SGD","IE0004086264.USD","LU2237443382.USD","IE0002270589.USD","PSQ","USJW.SI","BK4552","BK4533","BK4550","IE00BFXG1179.USD"],"gpt_icon":1},{"id":"2495343077","title":"Geron Corp. (GERN) Ends Trading Week Defying Market Bloodbath","url":"https://stock-news.laohu8.com/highlight/detail?id=2495343077","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495343077?lang=en_us&edition=fundamental","pubTime":"2024-12-28 22:52","pubTimestamp":1735397526,"startTime":"0","endTime":"0","summary":"A wave of selling gripped Wall Street this Friday, pushing major indices lower as investors shifted capital towards more attractive investment opportunities.Biotechnology company Geron Corp.  saw its share price increase by 1.52 percent on Friday to end at $3.35 apiece. Investors resorted to bargain hunting following a drop in its valuation on Thursday.Geron  recently announced that the European Medicines Agency's Committee for Medicinal Products for Human Use  has recommended approval of its drug Rytelo for treating specific types of myelodysplastic syndromes. The European Commission will now review this recommendation, with a final decision on market authorization expected in the coming months.Overall GERN ranks 4th on our list of the firms that ended the trading week defying market bloodbath. While we acknowledge the potential of GERN as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter ti","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geron-corp-gern-ends-trading-145206375.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","GERNW","CHMP","GERN","BK4087"],"gpt_icon":0},{"id":"2494863119","title":"Is Geron Corp. (GERN) the Biggest Loser of This Week?","url":"https://stock-news.laohu8.com/highlight/detail?id=2494863119","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494863119?lang=en_us&edition=fundamental","pubTime":"2024-12-26 21:17","pubTimestamp":1735219077,"startTime":"0","endTime":"0","summary":"Wall Street's main indices all finished in the green during a shortened trading session this week, yet 10 companies--mainly technology stocks-- still booked significant losses in their valuations. Let's take a look at the extent of each company's losses and the potential factors that could have dampened investor sentiment.To come up with the biggest losers this week, we considered only the stocks that have at least $2 billion in market capitalization and $5 million in daily trading volume.Geron Corp.  saw its shares drop by 4.3 percent to $3.34 from $3.49 apiece. Geron  is a biopharmaceutical company. Geron recently announced that the European Medicines Agency's Committee for Medicinal Products for Human Use  has recommended approvalof its drug Rytelo for treating specific types of myelodysplastic syndromes. The European Commission will now review this recommendation, with a final decision on market authorization expected in the coming months.Disclosure: None. This article is originall","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geron-corp-gern-biggest-loser-131757515.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CHMP","GERN","BK4087","GERNW","BK4139"],"gpt_icon":0},{"id":"2492441235","title":"Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A Deals","url":"https://stock-news.laohu8.com/highlight/detail?id=2492441235","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492441235?lang=en_us&edition=fundamental","pubTime":"2024-12-20 20:27","pubTimestamp":1734697620,"startTime":"0","endTime":"0","summary":"Here's a recap of the week’s most important stories.Pfizer announced encouraging guidance for 2025. In 2025, Pfizer expects to record total revenues between $61.0 billion and $64.0 billion. On an operational basis, revenues in 2025 are expected to rise in a range of approximately flat to 5% from the midpoint of 2024 guidance, excluding the impact of approximately $1.2 billion of non-recurring revenues for Paxlovid.Adjusted earnings are expected in the range of $2.80-$3.00, representing expected operational growth  in the range of 10%-18% year over year from the midpoint of the 2024 guidance, excluding the impact of certain non-recurring items.Merck announced that it is in-licensing exclusive global rights to develop, manufacture and commercializea preclinical GLP-1 receptor agonist, HS-10535, from Chinese biotech Hansoh Pharma. For the exclusive deal, Merck will make an upfront payment of $112 million to Hansoh Pharma, with the latter also being entitled to receive up to $1.9 billion i","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/cJ7Tfg7ljIEMGiDFsviYYw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/afe95824683969079aeba27c8210bd37","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/cJ7Tfg7ljIEMGiDFsviYYw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/afe95824683969079aeba27c8210bd37"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pharma-stock-roundup-pfes-2025-122700744.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE000M9KFDE8.USD","IE00BVYPNV92.GBP","LU0965509101.SGD","LU0738911758.USD","IE00BSNM7G36.USD","IE00BN8TJ469.HKD","IE00BVYPNW00.USD","IE00B2B36J28.USD","LU2112291526.USD","LU0795875086.SGD","LU1732800096.USD","LU0820561909.HKD","IE00BLSP4452.SGD","CHMP","LU0265550359.USD","SNY","LU0985481810.HKD","CD","IE00BJJMRZ35.SGD","LU0006306889.USD","BK4584","LU2361045086.USD","LU0266013472.USD","TEVA","BK4550","BK4557","ABBV","LU2087621335.USD","LU1496350171.SGD","LU0553294199.USD","LU0965509010.AUD","LU1496350502.SGD","MRK","LU2089284900.SGD","BK4585","LU0943347566.SGD","LU2237443382.USD","LU0321505439.SGD","IBD","LU2361044865.SGD","LU0208291251.USD","PFE","IE00B42XCP33.USD","SG9999015945.SGD","IE0004445239.USD","LU0029864427.USD","LU0256863902.USD","LU1093756325.SGD","IE00B19Z3581.USD","LU0708994859.HKD"],"gpt_icon":1},{"id":"2492623110","title":"GILD Obtains Positive CHMP Opinion for Liver Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2492623110","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492623110?lang=en_us&edition=fundamental","pubTime":"2024-12-17 02:40","pubTimestamp":1734374400,"startTime":"0","endTime":"0","summary":"Gilead Sciences, Inc. GILD announced that the Committee for Medicinal Products for Human Use  of the European Medicines Agency  recommended approval of seladelpar.The CHMP adopted a positive opinion recommending seladelpar for the treatment of primary biliary cholangitis  in combination with ursodeoxycholic acid  in adults who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA.A final decision from the European Commission is expected in the first quarter of 2025.Gilead’s shares have risen 14.3% year to date against the industry's decline of 11.4%.PBC is a rare, chronic inflammatory liver disease primarily affecting women. A potential approval will make seladelpar an important treatment option for people living with this rare liver disease in the EU.Last month, Gilead announced data from a two-and-a-half-year interim analysis of the ongoing phase III ASSURE study. The analysis showed that 81% of PBC patients treated with Livdelzi achieved a com","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/2Uxrul9Xalj9HwUZqlOfZA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/79b7ecb3a59852f0816e6eb69c31b2fe","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/2Uxrul9Xalj9HwUZqlOfZA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/79b7ecb3a59852f0816e6eb69c31b2fe"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gild-obtains-positive-chmp-opinion-184000443.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z3581.USD","IE00BKVL7J92.USD","IE00BSNM7G36.USD","BK4568","GSK.UK","BK4007","PBC","BK4087","BK4578","LU0109394709.USD","LU0234570918.USD","LU1839511570.USD","LU2468319806.SGD","LU0889565916.HKD","CHMP","BK4588","MRUS","BK4550","LU0058720904.USD","LU0289739699.SGD","LU1829250122.USD","IE00B19Z3B42.SGD","LU2087621335.USD","BK4585","LU1066051498.USD","LU0320765992.SGD","LU1430594728.SGD","LU1066053197.SGD","BK4139","IE0002270589.USD","GILD","IE00B7SZLL34.SGD","LU1571399168.USD","BK4566","IE00B3T34201.USD","GSK","BK4532","IE00BZ1G4Q59.USD","LU1585245621.USD","BK4583"],"gpt_icon":0},{"id":"2492661245","title":"CHMP Endorses Merck's Kidney Cancer Drug for Two Indications","url":"https://stock-news.laohu8.com/highlight/detail?id=2492661245","media":"Zacks","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492661245?lang=en_us&edition=fundamental","pubTime":"2024-12-16 23:57","pubTimestamp":1734364620,"startTime":"0","endTime":"0","summary":"Merck MRK announced that EMA’s Committee for Medicinal Products for Human Use  recommended granting conditional approval to its oral HIF-2α inhibitor, Welireg , for use in two indications associated with renal cell carcinoma .The CHMP recommended Welireg to treat adult patients with von Hippel-Lindau  disease who require therapy for associated RCC, central nervous system hemangioblastomas or pancreatic neuroendocrine tumors, not requiring immediate surgery. This committee also endorsed the drug for a second indication to treat adult patients with advanced RCC who have received at least two lines of therapy, which include anti-PD-1 and VEGF-targeted therapies.A final decision from the European Commission on both indications is expected in the first quarter of 2025. If approved, Welireg will be the first systemic treatment for patients with VHL disease-associated tumors in the European Union.The LITESPARK-004 study achieved its major efficacy endpoint, treatment with Welireg achieved an ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/1YvkxNLsEvDesNn9Nqp_Qw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/df847a6f57145ec8b42be7c65f980057","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/1YvkxNLsEvDesNn9Nqp_Qw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/df847a6f57145ec8b42be7c65f980057"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/chmp-endorses-mercks-kidney-cancer-155700240.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0965509283.SGD","CSTL","SPRO","LU1917777945.USD","LU1571399168.USD","LU1066051498.USD","LU2468319806.SGD","IE00BLSP4452.SGD","BK4007","IE00BBT3K403.USD","LU1057294990.SGD","SG9999015341.SGD","LU1941712348.USD","LU0266013472.USD","MRK","LU1983299246.USD","SG9999014567.USD","LU0965508806.USD","LU1066053197.SGD","IE00BFTCPJ56.SGD","BK4585","IE00B4R5TH58.HKD","SG9999013999.USD","BK4139","IE00BJT1NW94.SGD","LU1699723380.USD","LU0211331839.USD","LU0965509010.AUD","IE00B1BXHZ80.USD","LU1934455194.USD","CTMX","IE0009355771.USD","LU1989772840.SGD","SG9999015358.SGD","LU1291159041.SGD","LU0106261372.USD","LU2106854487.HKD","LU0058720904.USD","LU0265550359.USD","LU1037948897.HKD","BK4559","LU0861579265.USD","LU1430594728.SGD","LU0122379950.USD","LU2361044865.SGD","CHMP","IE00BSNM7G36.USD","LU2023250504.SGD","SG9999001176.SGD","SG9999001440.SGD"],"gpt_icon":0},{"id":"2491660053","title":"GSK announces CHMP of the EMA recommended expanding approval of Jemperli","url":"https://stock-news.laohu8.com/highlight/detail?id=2491660053","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491660053?lang=en_us&edition=fundamental","pubTime":"2024-12-16 20:35","pubTimestamp":1734352540,"startTime":"0","endTime":"0","summary":"GSK (GSK) announced the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has recommended expanding the ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gsk-announces-chmp-of-the-ema-recommended-expanding-approval-of-jemperli?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gsk-announces-chmp-of-the-ema-recommended-expanding-approval-of-jemperli?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1829250122.USD","GSK.UK","BK4087","CHMP","BK4585","BK4588","BK4007","BK4532","GSK"],"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":4,"totalSize":126,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CHMP\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CHMP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CHMP\",market:\"US\",delay:false,,,undefined,":{}}}